PMID- 33077561
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 19
TI  - Safety of furazolidone-containing regimen in Helicobacter pylori infection: a 
      systematic review and meta-analysis.
PG  - e037375
LID - 10.1136/bmjopen-2020-037375 [doi]
LID - e037375
AB  - OBJECTIVES: Furazolidone containing regimen is effectivefor Helicobacter pylori 
      (H. pylori) infection, but its safetyremains controversial. To assess the safety 
      of furazolidone containing regimenin H. pylori infection. DESIGN: A systematic 
      review and meta-analysis. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of 
      Science and Scopus databases were systematically searched for eligible randomised 
      controlled trials. ELIGIBILITY CRITERIA: Studies comparing furazolidone with 
      non-furazolidone-containing regimen, variable durations or doses of furazolidone 
      were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently 
      selected studies and extracted data. Primary outcomes were the risk of total 
      adverse events (AEs), serious AEs and severe AEs, expressed as relative risk (RR) 
      with 95% CI. Secondary outcomes contained the incidence of individual adverse 
      symptoms, AE-related treatment discontinuation and compliance. RESULTS: 
      Twenty-six articles were identified from 2039 searched records, of which 14 
      studies (n=2540) compared furazolidone with other antibiotics. The eradication 
      rates of furazolidone-containing regimen were higher than those of other 
      antibiotics in both intention-to-treat (RR 1.06, 95% CI 1.01 to 1.12) and 
      per-protocol analysis (RR 1.05, 95% CI 1.00 to 1.10). Only two serious AEs were 
      reported in furazolidone group (2/1221, 0.16%). No significant increased risk was 
      observed for the incidence of total AEs (RR 1.04, 95% CI 0.89 to 1.21) and severe 
      AEs (RR 1.81, 95% CI 0.91 to 3.60). Twelve studies (n=3139) compared different 
      durations of furazolidone, and four studies (n=343) assessed variable doses. 
      Elevated risk of total AEs and severe AEs were only found in a high daily dose of 
      furazolidone rather than prolonged duration. The incidence of AE-related 
      treatment discontinuation and compliance of patients were all similar, 
      irrespective of dose and duration adjustments. CONCLUSION: 
      Furazolidone-containing regimen has a similar risk of AEs and compliance as 
      non-furazolidone-containing regimen. A low daily dose of 200 mg is well-tolerated 
      for 14 day regimen and should be first considered. PROSPERO REGISTRATION NUMBER: 
      CRD42019137247.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ji, Chao-Ran
AU  - Ji CR
AD  - Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, Shangdong, China.
AD  - Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of 
      Medicine, Shandong University, Jinan, Shandong, China.
FAU - Liu, Jing
AU  - Liu J
AD  - Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, Shangdong, China.
AD  - Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of 
      Medicine, Shandong University, Jinan, Shandong, China.
FAU - Li, Yue-Yue
AU  - Li YY
AD  - Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, Shangdong, China.
AD  - Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of 
      Medicine, Shandong University, Jinan, Shandong, China.
FAU - Guo, Chuan-Guo
AU  - Guo CG
AD  - Department of Medicine, University of Hong Kong, Hong Kong, China.
FAU - Qu, Jun-Yan
AU  - Qu JY
AD  - Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, Shangdong, China.
AD  - Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of 
      Medicine, Shandong University, Jinan, Shandong, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, Shangdong, China.
AD  - Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of 
      Medicine, Shandong University, Jinan, Shandong, China.
FAU - Zuo, Xiuli
AU  - Zuo X
AUID- ORCID: 0000-0001-9556-8771
AD  - Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, Shangdong, China zuoxiuli@sdu.edu.cn.
AD  - Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of 
      Medicine, Shandong University, Jinan, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201019
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
RN  - 5J9CPU3RE0 (Furazolidone)
SB  - IM
MH  - Anti-Bacterial Agents/adverse effects
MH  - Drug Therapy, Combination
MH  - Furazolidone/adverse effects
MH  - *Helicobacter Infections/drug therapy
MH  - *Helicobacter pylori
MH  - Humans
PMC - PMC7574948
OTO - NOTNLM
OT  - gastroenterology
OT  - gastrointestinal infections
OT  - health & safety
COIS- Competing interests: None declared.
EDAT- 2020/10/21 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/10/19
CRDT- 2020/10/20 06:16
PHST- 2020/10/20 06:16 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/10/19 00:00 [pmc-release]
AID - bmjopen-2020-037375 [pii]
AID - 10.1136/bmjopen-2020-037375 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 19;10(10):e037375. doi: 10.1136/bmjopen-2020-037375.